2019
Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype
Montanari F, Deng C, Sawas A, Lue J, Marchi E, Radeski D, Cheng B, Bhagat G, O'Connor O. Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype. Blood 2019, 134: 2909. DOI: 10.1182/blood-2019-131841.Peer-Reviewed Original ResearchPost-transplant lymphoproliferative disorderDiffuse large B-cell lymphomaMonomorphic post-transplant lymphoproliferative disorderProgression-free survivalMedian progression-free survivalOverall survivalR-CHOPR-EPOCHGerminal centersCell of originImmunosuppressive therapyEBV infectionLymphoproliferative disordersTerms of PFSBetter progression-free survivalDLBCL subtypesCommon first-line therapySeattle GeneticsDiffuse large B-cell lymphoma (DLBCL) subtypeLarge B-cell lymphomaMonths-24 yearsComplete response rateMedian overall survivalPrimary refractory diseaseFirst-line therapy
2015
Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series
Montanari F, Radeski D, Seshan V, Alobeid B, Bhagat G, O'Connor OA. Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. British Journal Of Haematology 2015, 171: 491-500. PMID: 26250758, DOI: 10.1111/bjh.13621.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedChildChild, PreschoolCombined Modality TherapyEpstein-Barr Virus InfectionsFemaleHumansImmunosuppressive AgentsInfantLymphoproliferative DisordersMaleMiddle AgedMultivariate AnalysisOrgan TransplantationPostoperative ComplicationsPrognosisRisk AssessmentRituximabSeverity of Illness IndexYoung AdultConceptsPost-transplant lymphoproliferative disorderECOG scoreElderly patientsPediatric patientsLymphoproliferative disordersEastern Cooperative Oncology Group scoreECOG score 0Setting of immunosuppressionDecade of diagnosisNew prognostic scoreSingle-institution seriesHigh-risk groupAdult patientsOverall survivalPrognostic factorsPrognostic scoreInstitution seriesSingle institutionScore 0Tissue allograftsPatientsLarge seriesRisk categoriesHeterogeneous groupRecursive partitioning model
2014
The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma)
Radeski D, Hoehn D, Montanari F, Alobeid B, Zhang Y, Amengual J, Sawas A, Deng C, O’Connor O, Bhagat G. The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma). Blood 2014, 124: 4449. DOI: 10.1182/blood.v124.21.4449.4449.Peer-Reviewed Original ResearchMonomorphic post-transplant lymphoproliferative disorderPost-transplant lymphoproliferative disorderProgression-free survivalProlonged progression-free survivalCell of originAdvanced stage diseaseExtra-nodal involvementPrimary refractory diseaseFirst-line therapyR-CHOPR-EPOCHOverall survivalRituximab monotherapyLine therapyNodal involvementRefractory diseaseStage diseaseClinical presentationLymphoproliferative disordersTreatment regimensB cellsBone marrow/stem cell transplantationAutologous stem cell transplantCommon first-line therapyNon-germinal center B-cell
2010
Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series
Montanari F, Bhagat G, Seshan V, Clark-Garvey S, Zain J, Diefenbach C, McCormick E, Conroy M, Crook M, Alobeid B, O'Connor O. Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series. Blood 2010, 116: 4151. DOI: 10.1182/blood.v116.21.4151.4151.Peer-Reviewed Original ResearchPost-transplant lymphoproliferative disorderECOG score 0Epstein-Barr virusEpstein-Barr virus statusECOG scoreP-PTLDAdult patientsPediatric patientsScore 0Immunosuppression taperingM-PTLDRituximab groupMedian OSEarly lesionsLymphoproliferative disordersAdvanced stage III or IVPTLD subtypesIntermediate-low-risk groupSpectrum of lymphoproliferative disordersMedian OS of patientsIntermediate-high risk groupHematopoietic stem cell transplantationWorld Health Organization classification systemStage III or IVPopulation of adult patientsMonomorphic T-cell post-transplant lymphoproliferative disorders exhibit markedly inferior outcomes compared to monomorphic B-cell post-transplant lymphoproliferative disorders
Montanari F, Bhagat G, Clark-Garvey S, Seshan V, Zain J, Diefenbach C, Mccormick E, Crook M, Conroy M, O'connor OA. Monomorphic T-cell post-transplant lymphoproliferative disorders exhibit markedly inferior outcomes compared to monomorphic B-cell post-transplant lymphoproliferative disorders. Leukemia & Lymphoma 2010, 51: 1761-1764. PMID: 20807097, DOI: 10.3109/10428194.2010.500436.Peer-Reviewed Original ResearchT-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant.
Montanari F, Bhagat G, Zain J, Seshan V, Magid Diefenbach C, Clark-Garvey S, McCormick E, Crook M, Conroy M, O'Connor O. T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant. Journal Of Clinical Oncology 2010, 28: 8056-8056. DOI: 10.1200/jco.2010.28.15_suppl.8056.Peer-Reviewed Original ResearchMonomorphic post-transplant lymphoproliferative disorderPost-transplant lymphoproliferative disorderClinical characteristicsSerious complicationsLymphoproliferative disordersPrognostic assessmentComplicationsTransplant